Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

Author(s): Matthew P. Deek, MD1,2;Kim Van der Eecken, MD, PhD3;Philip Sutera, MD2;Rebecca A. Deek, MS4;Valérie Fonteyne, MD, PhD5;Adrianna A. Mendes, MD6;Karel Decaestecker, MD, PhD7;Ana Ponce Kiess, MD, PhD2;Nicolaas Lumen, MD, PhD5;Ryan Phillips, MD, PhD8;Aurélie De Bruycker, MD7;Mark Mishra, MD9;Zaker Rana, MD9;Jason Molitoris, MD, PhD9;Bieke Lambert, MD10;Louke Delrue, MD11;Hailun Wang, PhD2;Kathryn Lowe, BS2;Sofie Verbeke, MD, PhD12;Jo Van Dorpe, MD, PhD12;Renée Bultijnck, PhD7;Geert Villeirs, MD10;Kathia De Man, MD13;Filip Ameye, MD14;Daniel Y. Song, MD2;Theodore DeWeese, MD2;Channing J. Paller, MD15;Felix Y. Feng, MD16;Alexander Wyatt, PhD17;Kenneth J. Pienta, MD15,18;Maximillian Diehn, MD, PhD19;Soren M. Bentzen, PhD, DMsc9,20;Steven Joniau, MD, PhD21;Friedl Vanhaverbeke, MD22;Gert De Meerleer, MD23;Emmanuel S. Antonarakis, MD24;Tamara L. Lotan, MD6;Alejandro Berlin, MD25;Shankar Siva, MD, PhD26;Piet Ost, MD, PhD27,28;and Phuoc T. Tran, MD, PhD2,9,15,18 *M.P.D., K.V.d.E., P.O., and P.T.T. contributed equally to this work. P.O., and P.T.T. are co-senior authors.
Source: DOI: 10.1200/JCO.22.00644
Original Article
Professional photo of Lucio Gordan, MD
Fascinating report/study making salient points on the continued need to characterize patients’ neoplasm from a genomic standpoint and the impact of direct management of oligometastatic disease in patients with high-risk mutational signature.
The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1/2, Rb1, or TP53. The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk: 0.05; HR no high-risk: 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.

Author Affiliations

1Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ2Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD3Department of Pathology and Human Structure and Repair, University of Ghent, Ghent, Belgium4Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA5Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium6Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD7Department of Urology, Ghent University Hospital, Ghent, Belgium8Department of Radiation Oncology, Mayo Clinic, Rochester, MN9Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD10Department of Radiology and Nuclear Medicine, Ghent University, and Department of Nuclear Medicine, AZ Maria-Middelares Ghent, Belgium11Department of Radiology, Ghent University Hospital, Ghent, Belgium12Department of Pathology, Ghent University Hospital, Ghent, Belgium13Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium14Department of Urology, AZ Maria-Middelares Ghent, Ghent, Belgium15Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD16Departments of Medicine, Urology and Radiation Oncology, UCSF, San Francisco, CA17Department of Urologic Sciences, University of British Columbia, and Vancouver Prostate Centre, Vancouver, Canada18James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD19Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA20Department of Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD21Department of Urology, Catholic University Leuven, Leuven, Belgium22Department of Urology, AZ Nikolaas, Sint-Niklaas, Belgium23Department of Radiation Oncology, Catholic University Leuven, Leuven, Belgium24Department of Medicine, University of Minnesota School of Medicine, Minneapolis, MN25Department of Radiation Oncology, Princess Margaret Cancer Center, Toronto, Canada26Department of Radiation Oncology, Peter MacCallum Cancer Center, Melbourne Australia27Department of Radiation Oncology, Iridium Network, Antwerp, Belgium28Department of Human Structure and Repair, Ghent University, Ghent, Belgium *M.P.D., K.V.d.E., P.O., and P.T.T. contributed equally to this work. P.O., and P.T.T. are co-senior authors.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

An important post-hoc analysis from ARCHES and PROSPER that quantifies something we've suspected clinically, roughly 1 in 4 enzalutamide-treated patients who progress radiographically have no prostate-specific antigen (PSA) rise, and the majority won't meet PCWG2/3 PSA progression criteria. Liver metastases were 5-fold more common at radiographic progression on enzalutamide versus control, suggesting lineage plasticity and AR-independent clones are the culprit. Bottom line for practice: don't wait for PSA to rise before imaging your metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) patients on ARPIs, periodic cross-sectional imaging, especially in the first two years, is warranted regardless of PSA trend.

Read More »

Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer

Solid pragmatic phase II showing oxybutynin 2.5mg and 5mg BID (twice a day) both beat placebo for hot flash reduction in men on androgen-deprivation therapy (ADT), with no serious toxicities beyond expected dry mouth. Given that venlafaxine failed in this population and megestrol/medroxyprogesterone carry real concerns, this gives us an evidence-based option we can feel good about reaching for, especially in patients who also have urinary symptoms. Neurokinin B (NKB) antagonists are coming but not yet studied here, so oxybutynin fills a real gap now.

Read More »

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer

Moving PARP inhibition earlier into the hormone-sensitive androgen pathway modulation–sensitive (APMS) setting, this trial shows talazoparib plus enzalutamide cuts the risk of progression or death in half (HR 0.48) in HRR-altered metastatic prostate cancer, with an impressive 3-year progression-free survival (PFS) of 77% versus 56%. The benefit extends beyond BRCA1/2 to ATM and CDK12 as well, which is clinically meaningful given that two-thirds of this population was non-BRCA.

Read More »

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

Overall survival was 78.9% in the combination group compared with 69.5% in the leuprolide-alone group (HR 0.60). Enzalutamide monotherapy resulted in an overall survival of 73.1%, which was not statistically significant. We were already aware of the progression-free survival benefit; now we have overall survival data. This case was also presented in the MOC questions, where the correct answer was to add enzalutamide for a patient with a rising PSA on an LHRH agonist without imaging evidence of disease.

Read More »
Load More